26 results
8-K
EX-99.2
AGIO
Agios Pharmaceuticals Inc
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
Diseases Develop and deliver transformative medicines that elevate and extend the lives of patients Our Vision Our Values Our Mission Ryan Thalassemia
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
8 Jan 24
Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio
7:58am
its anticipated 2024 milestones and value-driving catalysts through 2026 that support the company’s mission to transform patient outcomes in rare
8-K
EX-99.1
AGIO
Agios Pharmaceuticals Inc
27 Oct 22
Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty
4:20pm
mission,” said Brian Goff, chief executive officer at Agios. “As the result of a competitive process, we achieved an attractive valuation for the TIBSOVO
8-K
EX-99.1
h39p9m0go72oqj0mq
19 Sep 22
Agios Appoints Cecilia Jones as Chief Financial Officer
7:08am
DEFA14A
49n8cps4cki7y5gjvtc3
12 Jan 21
Additional proxy soliciting materials
5:15pm
DEFA14A
EX-99.2
fulhjc6vqv22 5spy
21 Dec 20
Additional proxy soliciting materials
7:10am
8-K
EX-99.2
gwb8h
21 Dec 20
Regulation FD Disclosure
7:04am
8-K
EX-99.1
gjt8zh6k
12 Jun 20
Entry into a Material Definitive Agreement
7:04am
8-K
EX-99.1
7zewcx47
13 Jan 20
Regulation FD Disclosure
4:32pm